The effects of intravesical chemoimmunotherapy with gemcitabine and bacillus Calmette-Guérin in superficial bladder cancer

A preliminary study

D. Y. Cho, Jae Hyun Bae, Du Geon Moon, Jun Cheon, Jeong Gu Lee, Je-Jong Kim, D. K. Yoon, Hong Seok Park

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

This prospective study investigated the long-term effects of intravesical chemoimmunotherapy with gemcitabine (GEM) and bacillus Calmette-Guérin (BCG; n = 36) versus BCG alone (n = 51) for the treatment of superficial bladder cancer. For the chemoimmunotherapy (GEM + BCG) group, GEM (1000 mg) was instilled immediately after transurethral resection of bladder tumour (TURBT) and again (2000 mg) 1 week later. From 2 to 7 weeks after TURBT, BCG was instilled into the bladder of all patients once weekly. The recurrence-free period of the GEM + BCG group (24.13 months) was significantly longer than that of the BCG monotherapy group (19.81 months). The overall recurrence rate was similar between the groups, although at 6 and 9 months post-TURBT, GEM + BCG produced a significantly lower rate of recurrence compared with BCG alone. This study suggests that intravesical chemoimmunotherapy with GEM + BCG is effective in reducing early tumour recurrence and in prolonging the recurrence-free period of superficial bladder cancer.

Original languageEnglish
Pages (from-to)1823-1830
Number of pages8
JournalJournal of International Medical Research
Volume37
Issue number6
DOIs
Publication statusPublished - 2009 Jan 1

Fingerprint

gemcitabine
Bacilli
Mycobacterium bovis
Urinary Bladder Neoplasms
Bacillus
Tumors
Recurrence

Keywords

  • BCG
  • Gemcitabine
  • Intravesical chemoimmunotherapy
  • Recurrence rate
  • Superficial bladder cancer

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Biochemistry, medical

Cite this

@article{bbad6894e8b5419aa3e1d8944b46ae75,
title = "The effects of intravesical chemoimmunotherapy with gemcitabine and bacillus Calmette-Gu{\'e}rin in superficial bladder cancer: A preliminary study",
abstract = "This prospective study investigated the long-term effects of intravesical chemoimmunotherapy with gemcitabine (GEM) and bacillus Calmette-Gu{\'e}rin (BCG; n = 36) versus BCG alone (n = 51) for the treatment of superficial bladder cancer. For the chemoimmunotherapy (GEM + BCG) group, GEM (1000 mg) was instilled immediately after transurethral resection of bladder tumour (TURBT) and again (2000 mg) 1 week later. From 2 to 7 weeks after TURBT, BCG was instilled into the bladder of all patients once weekly. The recurrence-free period of the GEM + BCG group (24.13 months) was significantly longer than that of the BCG monotherapy group (19.81 months). The overall recurrence rate was similar between the groups, although at 6 and 9 months post-TURBT, GEM + BCG produced a significantly lower rate of recurrence compared with BCG alone. This study suggests that intravesical chemoimmunotherapy with GEM + BCG is effective in reducing early tumour recurrence and in prolonging the recurrence-free period of superficial bladder cancer.",
keywords = "BCG, Gemcitabine, Intravesical chemoimmunotherapy, Recurrence rate, Superficial bladder cancer",
author = "Cho, {D. Y.} and Bae, {Jae Hyun} and Moon, {Du Geon} and Jun Cheon and Lee, {Jeong Gu} and Je-Jong Kim and Yoon, {D. K.} and Park, {Hong Seok}",
year = "2009",
month = "1",
day = "1",
doi = "10.1177/147323000903700618",
language = "English",
volume = "37",
pages = "1823--1830",
journal = "Journal of International Medical Research",
issn = "0300-0605",
publisher = "Field House Publishing LLP",
number = "6",

}

TY - JOUR

T1 - The effects of intravesical chemoimmunotherapy with gemcitabine and bacillus Calmette-Guérin in superficial bladder cancer

T2 - A preliminary study

AU - Cho, D. Y.

AU - Bae, Jae Hyun

AU - Moon, Du Geon

AU - Cheon, Jun

AU - Lee, Jeong Gu

AU - Kim, Je-Jong

AU - Yoon, D. K.

AU - Park, Hong Seok

PY - 2009/1/1

Y1 - 2009/1/1

N2 - This prospective study investigated the long-term effects of intravesical chemoimmunotherapy with gemcitabine (GEM) and bacillus Calmette-Guérin (BCG; n = 36) versus BCG alone (n = 51) for the treatment of superficial bladder cancer. For the chemoimmunotherapy (GEM + BCG) group, GEM (1000 mg) was instilled immediately after transurethral resection of bladder tumour (TURBT) and again (2000 mg) 1 week later. From 2 to 7 weeks after TURBT, BCG was instilled into the bladder of all patients once weekly. The recurrence-free period of the GEM + BCG group (24.13 months) was significantly longer than that of the BCG monotherapy group (19.81 months). The overall recurrence rate was similar between the groups, although at 6 and 9 months post-TURBT, GEM + BCG produced a significantly lower rate of recurrence compared with BCG alone. This study suggests that intravesical chemoimmunotherapy with GEM + BCG is effective in reducing early tumour recurrence and in prolonging the recurrence-free period of superficial bladder cancer.

AB - This prospective study investigated the long-term effects of intravesical chemoimmunotherapy with gemcitabine (GEM) and bacillus Calmette-Guérin (BCG; n = 36) versus BCG alone (n = 51) for the treatment of superficial bladder cancer. For the chemoimmunotherapy (GEM + BCG) group, GEM (1000 mg) was instilled immediately after transurethral resection of bladder tumour (TURBT) and again (2000 mg) 1 week later. From 2 to 7 weeks after TURBT, BCG was instilled into the bladder of all patients once weekly. The recurrence-free period of the GEM + BCG group (24.13 months) was significantly longer than that of the BCG monotherapy group (19.81 months). The overall recurrence rate was similar between the groups, although at 6 and 9 months post-TURBT, GEM + BCG produced a significantly lower rate of recurrence compared with BCG alone. This study suggests that intravesical chemoimmunotherapy with GEM + BCG is effective in reducing early tumour recurrence and in prolonging the recurrence-free period of superficial bladder cancer.

KW - BCG

KW - Gemcitabine

KW - Intravesical chemoimmunotherapy

KW - Recurrence rate

KW - Superficial bladder cancer

UR - http://www.scopus.com/inward/record.url?scp=74949099046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74949099046&partnerID=8YFLogxK

U2 - 10.1177/147323000903700618

DO - 10.1177/147323000903700618

M3 - Article

VL - 37

SP - 1823

EP - 1830

JO - Journal of International Medical Research

JF - Journal of International Medical Research

SN - 0300-0605

IS - 6

ER -